Skip to main content
. 2021 Feb 3;14(4):706. doi: 10.3390/ma14040706

Table 2.

Commercially available clinically approved IONPs.

Name (Generic) Manufacturer Approved Indication Approval Date Regulatory Classification
Feraheme®
(ferumoxytol)		 AMAG Pharmaceuticals Iron deficient anemia in chronic kidney disease 2009 (FDA) a Drug
Resovist®
(ferucarbotran)		 FUJIFILM RI Pharma MRI imaging agent for liver 2002 (PMDA) b Drug
Nanotherm® MagForce Hyperthermic treatment of glioblastoma 2010 (CE mark) Device (class III)
Magtrace® c Endomag Sentinel lymph node biopsy for cancer staging 2011 (CE mark)
2018 (FDA)		 Device (class III)
Combination Product (class III)

a Approved by the EMA as Rienso® in 2012, but withdrawn in 2015 [119]; b approved by the EMA in 2001, but European distribution ceased in 2009 [120]; c formerly known as Sienna+®.